Cimzia Trial Shows Promise For Axial Spondyloarthritis And Ankylosing Spondylitis

According to UCB, certolizumab pegol achieved top-level results in a phase 3 study, which assessed the drug's efficacy and safety in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases, including ankylosing spondylitis (AS). Professor Dr Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President at UCB explained: "The population in this study included both patients with AS and with an early stage of the disease, called non-radiographic axial spondyloarthritis...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/fQYH7TCKlFc/244197.php

medical rehab sport